{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:47:17Z","timestamp":1784774837713,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"am","delay-in-days":278,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM104420"],"award-info":[{"award-number":["P20GM104420"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jad.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T15:01:50Z","timestamp":1738508510000},"page":"47-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression"],"prefix":"10.1016","volume":"376","author":[{"given":"Thomas T.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay D.","family":"Amsterdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.02.003_bb0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.02.003_bb0010","first-page":"606","article-title":"Monoamine oxidase inhibitor therapy in severe and resistant depression","volume":"36","author":"Amsterdam","year":"2006","journal-title":"Psychiatr. Ann."},{"key":"10.1016\/j.jad.2025.02.003_bb0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/JCP.0000000000001049","article-title":"Prior antidepressant treatment trials may predict a greater risk of depressive relapse during antidepressant maintenance therapy","volume":"39","author":"Amsterdam","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.02.003_bb0020","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2147\/NDT.S59107","article-title":"EMSAM (deprenyl patch): how a promising antidepressant was underutilized","volume":"10","author":"Asnis","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2025.02.003_bb0025","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"Association, A.P","year":"2000"},{"key":"10.1016\/j.jad.2025.02.003_bb0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH)","volume":"37","author":"Baber","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.02.003_bb0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/17512433.2016.1093416","article-title":"A critical appraisal of the selegiline transdermal system for major depressive disorder","volume":"8","author":"Bied","year":"2015","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.02.003_bb0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","article-title":"Multiple significance tests: the Bonferroni method","volume":"310","author":"Bland","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2025.02.003_bb0045","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.02.003_bb0050","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/17425247.2016.1140145","article-title":"Critical appraisal of selegiline transdermal system for major depressive disorder","volume":"13","author":"Cristancho","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jad.2025.02.003_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320970325","article-title":"May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance","volume":"10","author":"Fava","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jad.2025.02.003_bb0060","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.pnpbp.2010.07.026","article-title":"The mechanisms of tolerance in antidepressant action","volume":"35","author":"Fava","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.02.003_bb0065","first-page":"309","article-title":"Clinical management: imipramine\/placebo administration manual","volume":"23","author":"Fawcett","year":"1987","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jad.2025.02.003_bb0070","series-title":"ECDEU Assessment Manual for Psychopharmacology, revised","article-title":"Clinical Global Impressions","year":"1976"},{"key":"10.1016\/j.jad.2025.02.003_bb0075","series-title":"Not all Types of Depressed Patients Who Persist with their Antidepressant Treatment Improve in Side Effect Complaints: A Comparison of Treatment Completers and Dropouts in the STAR*D Trial","author":"Kim","year":"2024"},{"key":"10.1016\/j.jad.2025.02.003_bb0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jad.2019.03.028","article-title":"Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression","volume":"250","author":"Kim","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.02.003_bb0085","article-title":"Occurrence of side effects in treatment-resistant depression: role of clinical","volume":"12","author":"Levy","year":"2021","journal-title":"Socio-Demographic and Environmental Characteristics. Front Psychiatry"},{"key":"10.1016\/j.jad.2025.02.003_bb0090","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2025.02.003_bb0095","series-title":"Common Mental Health Disorders: The NICE Guideline on Identification and Pathways to Care","author":"NICE","year":"2011"},{"key":"10.1016\/j.jad.2025.02.003_bb0100","first-page":"1","article-title":"Methodological considerations for the study of treatment-resistant depression","volume":"2","author":"Nierenberg","year":"1991","journal-title":"Advances in neuropsychiatry and psychopharmacology"},{"key":"10.1016\/j.jad.2025.02.003_bb0105","series-title":"Major Depression","author":"NIMH","year":"2021"},{"key":"10.1016\/j.jad.2025.02.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063095","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jad.2025.02.003_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jad.2007.04.024","article-title":"The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability","volume":"105","author":"Robinson","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.02.003_bb0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euroneuro.2023.03.012","article-title":"Efficacy and safety of selegiline across different psychiatric disorders: a systematic review and meta-analysis of oral and transdermal formulations","volume":"72","author":"Rossano","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.02.003_bb0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., Thase, M.E., Nierenberg, A.A., Quitkin, F.M., Kashner, T.M., Kupfer, D.J., Rosenbaum, J.F., Alpert, J., Stewart, J.W., McGrath, P.J., Biggs, M.M., Shores-Wilson, K., Lebowitz, B.D., Ritz, L., Niederehe, G., Group, S.D.I","year":"2004","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.jad.2025.02.003_bb0130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4088\/JCP.v60n0308","article-title":"Refining the MAOI diet: tyramine content of pizzas and soy products","volume":"60","author":"Shulman","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.02.003_bb0135","series-title":"R: A Language and Environment for Statistical Computing","author":"Team","year":"2014"},{"key":"10.1016\/j.jad.2025.02.003_bb0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archpsyc.59.3.233","article-title":"Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression","volume":"59","author":"Thase","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.02.003_bb0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0893-133X(94)00058-8","article-title":"MAOIs in the contemporary treatment of depression","volume":"12","author":"Thase","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.02.003_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of Treatment-Resistant Depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2025.02.003_bb0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","article-title":"Self-rated global measure of the frequency, intensity, and burden of side effects","volume":"12","author":"Wisniewski","year":"2006","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.jad.2025.02.003_bb0160","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and National Burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J. Clin. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:38:02Z","timestamp":1750351082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S0165032725001909"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.02.003","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}